We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Identification of new drug targets to improve treatment options and reduce treatment-related toxicity for children diagnosed with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
In vitro evaluation of the potential of glucose restriction as an adjuvant therapy for paediatric brain tumours
In vitro modelling of MYCN-driven poor prognosis Wilms' tumour for assessment of novel therapies
Pre-clinical efficacy and biomarker studies of ALK, MAPK and MDM2-p53 inhibitor combinations in neuroblastoma
Screening for novel drug combinations in childhood B-cell acute lymphoblastic leukaemia
